As of December 15, 2025, Alexion Pharmaceuticals Inc (ALXN) reports a Net Margin of 9.94%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Alexion Pharmaceuticals Inc's Net Margin
Over recent years, Alexion Pharmaceuticals Inc's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2020-12-31 | 9.94% |
| 2019-12-31 | 48.17% |
| 2018-12-31 | 1.88% |
| 2017-12-31 | 12.48% |
| 2016-12-31 | 12.95% |
This slight downward trend highlights how Alexion Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Alexion Pharmaceuticals Inc's Net Margin to Peers
To better understand Alexion Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Alexion Pharmaceuticals Inc (ALXN) | 9.94% |
| Agios Pharmaceuticals Inc (AGIO) | 1845.92% |
| China Biologic Products Holdings Inc (CBPO) | 29.04% |
| Exelixis Inc (EXEL) | 24.04% |
| ACADIA Pharmaceuticals Inc (ACAD) | 23.64% |
| Biogen Inc (BIIB) | 16.87% |
Compared to its competitors, Alexion Pharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.